Myriad
360Dx Top 30 Starts the Year up 1 Percent
Of the 30 companies in the index, 22 saw their share prices increase while eight saw stock prices drop.
The company is planning to launch a 4-in-1 prenatal screening test, a liquid biopsy test, and a minimal residual disease assay in the coming year.
Myriad expects new product launches, strategic mergers, positive reimbursement decisions, and rising test volumes to drive growth despite current sagging revenues.
The company, infamous and long derided in the genetic testing community for refusing to share BRCA1/2 variants, has decided to change its stance as part of a "strategic transformation."
California Court Temporarily Stops State From Barring Other Labs Performing Trisomy Screenings
A California court barred the state's Department of Public Health from enacting a new requirement that only select labs perform trisomy screening in the state.